Bafna Pharma Q2 FY27: PAT doubles YoY to ₹6.85 Cr on margin expansion, revenue +34%
PAT +119.1% YoY · revenue +34.4% · margins expanding
₹47.67 Cr
+34.4% YoY
₹6.85 Cr
+119.1% YoY
14.04%
+5.5pp YoY
₹2.89
Bafna Pharmaceuticals reported standalone Q2 FY27 (quarter ended September 30, 2026) revenue of ₹47.67 Cr, up 34.4% YoY from ₹35.47 Cr, and net profit of ₹6.85 Cr, up 119% YoY from ₹3.12 Cr — standalone is the only basis reported, as the filing carries no consolidated statement. EPS rose to ₹2.89 from ₹1.32. Neither period carries an exceptional item, so the headline YoY growth is also the adjusted growth. Sequentially revenue rose 79.3% and profit swung from a near-breakeven ₹0.08 Cr in Q1 FY27 (a seasonal low), so the QoQ profit comparison is not meaningful off that tiny base and shouldn't be read as the story.
Q2 FY-2027 vs prior quarters
The growth came with genuine margin expansion rather than a one-off: net margin widened to 14.4% from 8.5% a year earlier, and OPM (EBITDA/revenue) widened to 18.1% from 12.1%, pointing to operating leverage on higher volumes. Separately, the company again recorded zero tax expense this quarter, so the full ₹6.85 Cr PBT flowed through to PAT — the same pattern as the year-ago quarter — worth watching for whether this is a sustained tax-shield effect or the effective rate normalizes in a future quarter.
The stock went into the print at ₹484.5, up 11.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
There is no prior management guidance or concall commentary on record for this quarter, and a web search found no analyst or brokerage preview/consensus estimate for this micro-cap print, so the vsStreet and vsGuidance verdicts are unknown; no management press release beyond the regulatory filing was available to cross-check management's own framing of the quarter. Separately, the statutory auditor flagged (emphasis of matter, not a qualification) an ongoing GST dispute — a ₹235.47 Lakh demand under appeal and a ₹331.09 Lakh refund-recovery order stayed by the Madras High Court — management says it does not anticipate an adverse outcome and has made no provision; this sits outside the P&L for now but is a contingent liability worth tracking into subsequent quarters.
W1
GST litigation outcome — ₹235.47 Lakh demand (under appeal) and ₹331.09 Lakh refund-recovery order (HC stay) — a loss would create a liability not currently provided for
W2
Whether OPM (18.1% this quarter vs 12.1% a year ago) holds into Q3 FY27 or reverts toward prior-year levels
W3
Effective tax rate — two straight quarters (this one and year-ago) of zero tax expense; watch if/when tax becomes payable